Regenerative medicine company Athersys Inc. (NASDAQ: ATHX) of Cleveland is in the market for a new CEO. The developer of the MultiStem cell therapy announced on Tuesday morning, Feb. 16, that Dr. Gil ...

Athersys Inc (NASDAQ:ATHX) shares are trading higher by 31.63% to $1.54 Friday morning after the company announced it entered into amended agreements to extend the exercise period of the warrants that ...

Cleveland biotechnology company Athersys Inc. (NASDAQ:ATHX) has reached an agreement with Japanese drugmaker Healios KK to broaden their collaboration into new therapeutic areas. Under terms of the ...

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of ...

Sept. 21, 2010, 11:16 AM UTC / Source: GlobeNewswire CLEVELAND, Sept. 21, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that MultiStem®, Athersys' multipotent adult progenitor ...

Athersys, Inc. ATHX is a Biomedical and Genetics company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing ...

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of ...

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in ...

Athersys, Inc. ATHX was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal ...

CLEVELAND, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at ...